Stockscreener 앱 받기
2.0209
0.97%
-0.0391
전일 마감가:
$2.06
열려 있는:
$2
하루 거래량:
3,120
Relative Volume:
0.02
시가총액:
$75.97M
수익:
-
순이익/손실:
$-13.27M
주가수익비율:
-12.32
EPS:
-0.164
순현금흐름:
$-7.70M
1주 성능:
+6.81%
1개월 성능:
-9.09%
6개월 성능:
-32.23%
1년 성능:
+92.45%
1일 변동 폭
$1.9808
$2.02
1주일 범위
$1.92
$2.40
52주 변동 폭
$0.9016
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
OKYO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.02 | 77.48M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.49 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.98 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
842.80 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.79 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.79 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 개시 | B. Riley Securities | Buy |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
Okyo Pharma executive chairman increases stake in company By Investing.com - Investing.com South Africa
Panetta Partners increases stake in OKYO Pharma with new share purchase By Investing.com - Investing.com South Africa
OKYO Pharma Chairman Increases Stake Amid Promising Drug Trials - TipRanks
OKYO Pharma Announces Chairman and Founder Acquires Shares - The Manila Times
Small cap wrap: AtaiBeckley, OKYO Pharma, New Era Energy & Digital, Century Lithium… - Proactive financial news
OKYO Pharma reports favorable outcomes from Phase 2 neuropathic corneal pain study - Proactive financial news
OKYO’s urcosimod shows potential nerve regeneration in corneal pain trial By Investing.com - Investing.com Australia
OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain - TipRanks
OKYO’s urcosimod shows potential nerve regeneration in corneal pain trial - Investing.com
OKYO Pharma Reports Encouraging Phase 2 Trial Results for Urcosimod in Neuropathic Corneal Pain - Quiver Quantitative
OKYO Pharma Announces New Data Showing Favorable Corneal - GlobeNewswire
B. Riley Begins Coverage on OKYO Pharma (NASDAQ:OKYO) - Defense World
B. Riley Initiates Coverage on OKYO Pharma (NASDAQ:OKYO) - MarketBeat
B. Riley Initiates Coverage on OKYO Pharma With Buy Rating, $5 Price Target - marketscreener.com
B.Riley initiates coverage on OKYO Pharma stock with Buy rating - Investing.com Nigeria
How OKYO Pharma Limited (OK11) stock compares with top peersGlobal Markets & Long-Term Safe Investment Plans - Newser
What is the fair value estimate for OKYO Pharma Limited (OK11) stock in 2025Market Sentiment Report & Technical Pattern Alert System - Newser
Is OKYO Pharma Limited (OK11) stock a top pick for value investors2025 Trade Ideas & AI Powered Market Entry Strategies - Newser
Okyo Pharma chairman acquires 27,051 company shares - MSN
Is OKYO Pharma Limited stock trading near support levelsWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
OKYO Pharma chairman-linked entity acquires additional shares on NASDAQ By Investing.com - Investing.com Australia
OKYO Pharma chairman-linked entity acquires additional shares on NASDAQ - Investing.com
OKYO Pharma’s Chairman Increases Stake Amidst Phase 2 Trial Completion - TipRanks
Gabriele Cerrone increases stake in OKYO Pharma with share purchase - Investing.com
OKYO Pharma Limited Executive Chairman Gabriele Cerrone Acquires Additional Shares in Company - Quiver Quantitative
Gabriele Cerrone increases stake in OKYO Pharma with share purchase By Investing.com - Investing.com UK
OKYO Pharma (NASDAQ: OKYO) chairman raises holding after buying 27,051 shares - Stock Titan
Why OKYO Pharma Limited stock is a must watch in 2025Market Growth Report & Comprehensive Market Scan Reports - Newser
OKYO Pharma executive chair increases stake with additional share purchase - Proactive financial news
OKYO Pharma (OKYO) Stock Analysis Report | Financials & Insights - Benzinga
Holdings of OKYO Pharma Limited (OKYO) are aligned with the stars - Setenews
Decliners Report: Will OKYO Pharma Limited stock remain a Wall Street favoriteRecession Risk & Advanced Swing Trade Entry Plans - moha.gov.vn
Okyo Pharma chairman acquires 82,018 company shares - MSN
Panetta Partners increases stake in OKYO Pharma with purchase of 82,018 shares - Investing.com Australia
OKYO Pharma founder increases his buys shares - Proactive financial news
Operating cash flow per share of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Okyo Pharma chairman increases stake with new share acquisition By Investing.com - Investing.com Nigeria
OKYO Pharma stock rises after Chairman increases stake By Investing.com - Investing.com Nigeria
OKYO Pharma stock rises after Chairman increases stake - Investing.com India
OKYO Pharm Chairman and Founder acquires shares - MSN
OKYO Pharma’s Chairman Increases Stake with Recent Share Acquisition - TipRanks
Okyo Pharma chairman increases stake with new share acquisition - Investing.com India
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
1.23%
자본화:
|
볼륨(24시간):